Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Novacea Reports Third Quarter 2008 Financial Results
Nov 10, 2008 04:32 PM
- Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Oct 22, 2008 09:01 AM
- Novacea, Inc. and Transcept Pharmaceuticals, Inc. Announce Filing of Form S-4 Proxy/Registration Statement
Oct 06, 2008 08:30 AM
- Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Oct 01, 2008 09:02 AM
- Novacea Update on Asentar(TM)
Sep 11, 2008 11:29 AM
- Novacea, Inc. and Transcept Pharmaceuticals, Inc. to Hold Conference Call to Discuss Signing of Merger Agreement
Sep 02, 2008 07:00 AM
- Novacea, Inc. and Transcept Pharmaceuticals, Inc. Sign Merger Agreement
Sep 02, 2008 01:00 AM
- Novacea Reports Second Quarter 2008 Financial Results
Aug 11, 2008 05:33 PM
- Novacea Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial
Jun 04, 2008 07:30 AM
- Novacea Reports First Quarter 2008 Financial Results
May 12, 2008 04:05 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
NOVC
|
Compare to S&P
|
| YTD |
-62.08 %
|
-24.95 %
|
| 4 Weeks |
2.73 %
|
14.22 %
|
| 12 Weeks |
-52.12 %
|
-23.92 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -114.84 %
|
|
EPS Growth in Last Year: -107.69 %
|
|
Sales Growth in Last Quarter: -99.83 %
|
|
Sales Growth in Last Quarter: -98.91 %
|
|
|
